Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Tolebrutinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Relapsing Multiple Sclerosis & Multiple Sclerosis) and 6,541 total planned enrollment. 5 Phase 3 Tolebrutinib trials and 2 Phase 2 are listed. Most recent activity: NCT06372145 (Apr 2029).
Tolebrutinib clinical trials at a glance: phase × recruitment status
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
P2
unknown
12
National Institute of Neurological Disorders and Stroke (NINDS)
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
11 Tolebrutinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 9 are marked completed.
Are Tolebrutinib clinical trials recruiting in 2026?
No active Tolebrutinib trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
What conditions is Tolebrutinib being studied for?
Tolebrutinib is being studied for Relapsing Multiple Sclerosis, Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis, Renal Impairment and 3 more. The trials are grouped by indication on this page.
What phase is Tolebrutinib in?
Tolebrutinib clinical trials span 5 Phase 3, 2 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tolebrutinib clinical trials?
The lead sponsor across the most Tolebrutinib trials is Sanofi, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tolebrutinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.